Table 3.
Effect of niacin on mineral metabolism parameters in CKD participants in the AIM-HIGH Trial (as treated analysis)
| Variables | Placebo | Niacin | P Value |
|---|---|---|---|
| Phosphate, mg/dl | |||
| Baseline, n=132, mean±SD | 3.5±0.5 | 3.4±0.6 | 0.52 |
| Year 1, n=132, mean±SD | 3.4±0.6 | 3.4±0.6 | 0.60 |
| Year 3, n=132, mean±SD | 3.6±0.5 | 3.3±0.5 | <0.01 |
| Difference in slopes (95% CI) | −0.07 (−0.13 to −0.01) | 0.02 | |
| Intact FGF23, pg/ml | |||
| Baseline, n=136, median (IQR) | 58 (55–90) | 66 (51–88) | 0.61 |
| Year 1, n=136, median (IQR) | 72 (54–97) | 68 (55–89) | 0.39 |
| Year 3, n=136, median (IQR) | 73 (54–96) | 75 (57–103) | 0.86 |
| Difference in slopes (95% CI) | 0.55 (−5.17 to 6.27) | 0.85 | |
| Calcium, mg/dl | |||
| Baseline, n=127, mean±SD | 9.6±0.5 | 9.7±0.6 | 0.36 |
| Year 1, n=127, mean±SD | 9.6±0.5 | 9.6±0.5 | 0.55 |
| Year 3, n=127, mean±SD | 9.6±0.5 | 9.7±0.6 | 0.67 |
| Difference in slopes (95% CI) | −0.02 (−0.07 to 0.05) | 0.64 | |
| Intact PTH, pg/ml | |||
| Baseline, n=135, median (IQR) | 53 (39–80) | 52 (40–78) | 0.86 |
| Year 1, n=135, median (IQR) | 52 (31–75) | 44 (31–66) | 0.20 |
| Year 3, n=135, median (IQR) | 51 (34–79) | 44 (35–71) | 0.80 |
| Difference in slopes (95% CI) | −1.74 (−4.93 to 1.44) | 0.28 | |
| 25-Hydroxyvitamin D, ng/ml | |||
| Baseline, n=122, mean±SD | 25±9 | 25±9 | 0.70 |
| Year 1, n=122, mean±SD | 25±9 | 24±9 | 0.50 |
| Year 3, n=122, mean±SD | 29±10 | 29±10 | 0.34 |
| Difference in slopes (95% CI) | −0.73 (−1.73 to 0.27) | 0.15 | |
| 1,25-Dihydroxyvitamin D, ng/ml | |||
| Baseline, n=122, mean±SD | 32±11 | 34±12 | 0.25 |
| Year 1, n=122, mean±SD | 33±11 | 32±10 | 0.64 |
| Year 3, n=122, mean±SD | 33±12 | 33±13 | 0.90 |
| Difference in slopes (95% CI) | −0.46 (−1.84 to 0.91) | 0.51 | |
| 24,25-Dihydroxyvitamin D, ng/ml | |||
| Baseline, n=122, mean±SD | 2.7±1.7 | 2.6±1.4 | 0.84 |
| Year 1, n=122, mean±SD | 2.7±1.7 | 2.6±1.4 | 0.60 |
| Year 3, n=122, mean±SD | 3.1±1.6 | 2.9±1.6 | 0.53 |
| Difference in slopes (95% CI) | −0.05 (−0.20 to 0.11) | 0.57 | |
AIM-HIGH, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health; 95% CI, 95% confidence interval; FGF23, fibroblast growth factor 23; IQR, interquartile range; PTH, parathyroid hormone.